Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers

  • Adaptimmune Therapeutics plc ADAP announces data from its signal-finding Phase 1 SURPASS trial of ADP-A2M4CD8 in solid tumor settings. The data will be presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
  • The Phase 1 SURPASS trial is ongoing, and the overall response rate for the 43 evaluable people is 33% (including confirmatory scans for two people with unconfirmed partial responses).
  • Most people experienced meaningful antitumor activity with a disease control rate of 81%. The median duration of response was 12 weeks.
  • For the subset of 25 people with ovarian, urothelial, and head & neck cancers, the response rate is 44%.
  • In ovarian cancer patients, most people had reductions in target lesions and an 86% disease control rate, and 5 (36%) had confirmed clinical responses, including one complete response.
  • The company plans to start Phase 2 SURPASS-3 trial in late 2022/early 2023 in ovarian cancer.
  • In urothelial cancer, 6 out of 7 people had reductions in target lesions, and three had confirmed responses. In addition, one unconfirmed response was received after the data cut-off.
  • In head & neck cancer, three confirmed responses out of 4 people were observed.
  • In gastroesophageal cancers, one confirmed and one unconfirmed response was subsequently confirmed after the data cut-off. There is clear antitumor activity in these cancers with an encouraging disease control rate (10 out of 13 people) in this heavily pre-treated advanced population.
  • Price Action: ADAP shares are down 1.47% at $2.01 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!